News

OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...
GRI Bio, Inc.: GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")
Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recomm ...
Alkermes: A More Than Solid Quarter
Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.
Thorax5d
Association between ultra-processed food consumption and lung cancer risk: a population-based cohort study
Background The evidence on associations between ultra-processed foods (UPF) and lung cancer risk is limited and inconsistent.
Metsera, Inc.: Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress
VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...
BMJ Open6d
Pulmonary rehabilitation for patients receiving lung cancer radiotherapy: a scoping review
Objective Radiotherapy (RT) can cause a range of negative impacts in addition to the intended treatment impacts. Pulmonary rehabilitation (PR) may improve the physical and psychological conditions of ...